NCT02790034: A trial that was reported late by Newron Pharmaceuticals SPA
This trial has reported, although it was 432 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02790034 |
|---|---|
| Title | A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 26, 2016 |
| Completion date | Aug. 6, 2019 |
| Required reporting date | Aug. 5, 2020, midnight |
| Actual reporting date | Oct. 12, 2021 |
| Date last checked at ClinicalTrials.gov | Jan. 21, 2026 |
| Days late | 432 |